3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorderRecruitingPhase 22026-10-07NCT07282574
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisCNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorderActive, not recruitingPhase 32026-07-29NCT05269004
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisCNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Multiple Sclerosis, Primary Progressive, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorderActive, not recruitingPhase 32026-02-23NCT04035005